862283-71-4 Usage
Description
4-(4-Chlorophenyl)pyrrolidine-3-methylcarboxylate hydrochloride is a chemical compound that is a derivative of pyrrolidine, a five-membered heterocyclic ring containing a nitrogen atom. 4-(4-CHLOROPHENYL)PYRROLIDINE-3-METHYLCARBOXYLATE HYDROCHLORIDE contains a methylcarboxylate group attached to the third position of the pyrrolidine ring, and a 4-chlorophenyl group attached to the fourth position. The hydrochloride salt form of this compound is commonly used in research and pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
4-(4-Chlorophenyl)pyrrolidine-3-methylcarboxylate hydrochloride is used as a synthetic intermediate for the production of other chemical compounds. It may be used in the synthesis of pharmaceuticals or other bioactive molecules.
Used in Research Applications:
4-(4-Chlorophenyl)pyrrolidine-3-methylcarboxylate hydrochloride is used as a building block in research applications to explore its potential pharmacological or physiological effects. Further research is likely needed to fully understand its properties and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 862283-71-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,2,2,8 and 3 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 862283-71:
(8*8)+(7*6)+(6*2)+(5*2)+(4*8)+(3*3)+(2*7)+(1*1)=184
184 % 10 = 4
So 862283-71-4 is a valid CAS Registry Number.
862283-71-4Relevant articles and documents
Structure-based design of potent and selective leishmania N -myristoyltransferase inhibitors
Hutton, Jennie A.,Goncalves, Victor,Brannigan, James A.,Paape, Daniel,Wright, Megan H.,Waugh, Thomas M.,Roberts, Shirley M.,Bell, Andrew S.,Wilkinson, Anthony J.,Smith, Deborah F.,Leatherbarrow, Robin J.,Tate, Edward W.
supporting information, p. 8664 - 8670 (2015/01/09)
Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmaniasis, obtained from a high-throughput screen, were resynthesized to validate activity. Crystal structures bound to Leishmania major NMT were obtained,
